Fecal Recovery of Probiotics Administered as a Multi-Strain Formulation during Antibiotic Treatment

Sofia D Forssten, Nicolas Yeung, Arthur C Ouwehand, Sofia D Forssten, Nicolas Yeung, Arthur C Ouwehand

Abstract

The present study aimed to investigate whether probiotic recovery is affected when consumed together with antibiotics. Fecal samples were collected from an earlier antibiotic associated diarrhea, randomized, placebo-controlled study with a product consisting of a combination of Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, and Bifidobacterium lactis Bi-07, B. lactis Bl-04 at equal numbers and at a total dose of 1010 CFU. Fecal samples were collected during the screening visit (T0), i.e., at the time of antibiotic prescription, and then on the last day of the antibiotic treatment (T1) as well as seven days after the subject had stopped taking the antibiotic treatment (T2) and at two weeks after completing antibiotic treatment and one week after probiotic/placebo consumption stopped (T3). Samples were analyzed for the presence of the four administered strains. The study was registered at clinicaltrials.gov as NCT01596829. Detection levels of all four strains were significantly increased from T0 to T1 and returned to baseline level from T2 to T3. There were also significantly more subjects with detectable levels of L. paracasei Lpc-37, B. lactis Bi-07, and B. lactis Bl-04 at T1 and T2 compared to T0 and T3, and compared to placebo. Each of the four strains could be detected in the feces of patients apparently unaffected by the simultaneous consumption of antibiotics.

Keywords: AAD; Antibiotic associated diarrhea; Bifidobacterium lactis; Fecal recovery; Lactobacillus acidophilus; Lactobacillus paracasei; probiotic.

Conflict of interest statement

The authors are employees of DuPont Nutrition and Biosciences, which manufactures and markets the investigated probiotics. The authors declare no other conflicts of interest.

Figures

Figure 1
Figure 1
Schematic representation of fecal sample collection and study timeline. T0 is baseline, T1 is at the end of antibiotic treatment, T2 is one week after antibiotic treatment was stopped and the last day of probiotic supplementation, and T3 is two weeks after antibiotic treatment was stopped and one week after probiotic supplementation was stopped.
Figure 2
Figure 2
Mean levels (±SE) for Log10 detected genomes per gram feces for the three target strains; Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, Bifidobacterium lactis Bi-07, and B. lactis Bl-04 in the probiotic group for the four sampling times. Where T0 = baseline, T1 = end of antibiotic treatment, T2 = end of probiotic treatment, and T3 = one week after end of probiotic treatment (washout). * Indicates significant changes from previous time point.
Figure 3
Figure 3
Mean levels (±SE) for Log10 detected genomes per gram feces for the target strains; Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, Bifidobacterium lactis Bi-07, and B. lactis Bl-04 in the placebo group for the four sampling times. Where T0 = baseline, T1 = end of antibiotic treatment, T2 = end of Placebo treatment, and T3 = one week after end of placebo treatment (washout). * Indicates significant changes from previous time point.

References

    1. Wiström J., Norrby S.R., Myhre E.B., Eriksson S., Granström G., Lagergren L., Englund G., Nord C.E., Svenungsson B. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: A prospective study. J. Antimicrob. Chemother. 2001;47:43–50. doi: 10.1093/jac/47.1.43.
    1. McFarland L.V. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig. Dis. 1998;16:292–307. doi: 10.1159/000016879.
    1. McFarland L.V. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am. J. Gastroenterol. 2006;101:812–822. doi: 10.1111/j.1572-0241.2006.00465.x.
    1. Haran J.P., Hayward G., Skinner S., Merritt C., Hoaglin D.C., Hibberd P.L., Lu S., Boyer E.W. Factors influencing the development of antibiotic associated diarrhea in ED patients discharged home: Risk of administering IV antibiotics. Am. J. Emerg. Med. 2014;32:1195–1199. doi: 10.1016/j.ajem.2014.07.015.
    1. Blaabjerg S., Artzi D.M., Aabenhus R. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Outpatients-A Systematic Review and Meta-Analysis. Antibiotics. 2017;6:21. doi: 10.3390/antibiotics6040021.
    1. Ouwehand A.C., DongLian C., Weijian X., Stewart M., Ni J., Stewart T., Miller L.E. Probiotics reduce symptoms of antibiotic use in a hospital setting: A randomized dose response study. Vaccine. 2014;32:458–463. doi: 10.1016/j.vaccine.2013.11.053.
    1. Forssten S.D., Ouwehand A.C. Simulating colonic survival of probiotics in single-strain products compared to multi-strain products. Microb. Ecol. Health Dis. 2017;28:1378061. doi: 10.1080/16512235.2017.1378061.
    1. Hansen S.J.Z., Morovic W., DeMeules M., Stahl B., Sindelar C.W. Absolute Enumeration of Probiotic Strains Lactobacillus acidophilus NCFM® and Bifidobacterium animalis subsp. lactis Bl-04® via Chip-Based Digital PCR. Front. Microbiol. 2018;9:704. doi: 10.3389/fmicb.2018.00704.
    1. Airaksinen K., Yeung N., Lyra A., Lahtinen S.J., Huttunen T., Shanahan F., Ouwehand A.C. The effect of a probiotic blend on gastrointestinal symptoms in constipated patients: A double blind, randomised, placebo controlled 2-week trial. Benef. Microbes. 2019;10:616–627. doi: 10.3920/BM2018.0163.
    1. Haarman M., Knol J. Quantitative real-time PCR analysis of fecal Lactobacillus species in infants receiving a prebiotic infant formula. Appl. Environ. Microbiol. 2006;72:2359–2365. doi: 10.1128/AEM.72.4.2359-2365.2006.
    1. Poutsiaka D.D., Mahoney I.J., McDermott L.A., Stern L.L., Thorpe C.M., Kane A.V., Baez-Giangreco C., McKinney J., Davidson L.E., Leyva R., et al. Selective method for identification and quantification of Bifidobacterium animalis subspecies lactis BB-12 (BB-12) from the gastrointestinal tract of healthy volunteers ingesting a combination probiotic of BB-12 and Lactobacillus rhamnosus GG. J. Appl. Microbiol. 2017;122:1321–1332. doi: 10.1111/jam.13436.
    1. Ouwehand A.C., Nermes M., Collado M.C., Rautonen N., Salminen S., Isolauri E. Specific probiotics alleviate allergic rhinitis during the birch pollen season. World J. Gastroenterol. 2009;15:3261–3268. doi: 10.3748/wjg.15.3261.
    1. Ouwehand A.C., ten Bruggencate S.J., Schonewille A.J., Alhoniemi E., Forssten S.D., Bovee-Oudenhoven I.M. Lactobacillus acidophilus supplementation in human subjects and their resistance to enterotoxigenic Escherichia coli infection. Br. J. Nutr. 2014;111:465–473. doi: 10.1017/S0007114513002547.
    1. Hemalatha R., Ouwehand A.C., Forssten S.D., Babu Geddan J.J., Sriswan Mamidi R., Bhaskar V., Radhakrishna K.V. A Community-based Randomized Double Blind Controlled Trial of Lactobacillus paracasei and Bifidobacterium lactis on Reducing Risk for Diarrhea and Fever in Preschool Children in an Urban Slum in India. Eur. J. Nutr. Food Saf. 2014;4:325–342. doi: 10.9734/EJNFS/2014/8280.
    1. Bettler J., Mitchell D.K., Kullen M.J. Administration of Bifidobacterium lactis with fructo-oligosaccharides to toddlers is safe and results in transient colonization. Int. J. Probiotics Prebiotics. 2006;1:193–202.
    1. Forssten S., Evans M., Wilson D., Ouwehand A.C. Influence of a probiotic mixture on antibiotic induced microbiota disturbances. World J. Gastroenterol. 2014;20:11878–11885. doi: 10.3748/wjg.v20.i33.11878.
    1. Morovic W., Roper J.M., Smith A.B., Mukerji P., Stahl B., Rae J.C., Ouwehand A.C. Safety evaluation of HOWARU Restore® (Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, Bifidobacterium animalis subsp. lactis Bl-04 and B. lactis Bi-07) for antibiotic resistance, genomic risk factors, and acute toxicity. Food Chem. Toxicol. 2017;110:316–324. doi: 10.1016/j.fct.2017.10.037.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever